| Aktie | Ticker | Breite | GCS | 2026/Q1 | 2025/Q4 | 2025/Q3 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | ||||
| 47.884.476 $ | +14.085.048 $ | +11,7 % | 2 | 33.799.428 $ | -30.935.718 $ | -41,5 % | 2 | 700.444.832 $ | -784.557.877 $ | +42,9 % | 4 | ||||
| ALNYLAM PHARMACEUTICALS, INC. | ALNY | → 0 | Neutral | 634.890.168 $ | -814.398.902 $ | -56,2 % | 1 | ||||||||
| Intellia Therapeutics, Inc. | NTLA | → 0 | Neutral | 47.472.396 $ | +14.182.471 $ | +42,6 % | 1 | 33.289.925 $ | -30.660.799 $ | -47,9 % | 1 | 63.950.724 $ | +29.216.631 $ | +84,1 % | 1 |
| Adverum Biotechnologies, Inc. | ADVM | → 0 | 819.518 $ | +430.564 $ | +110,7 % | 1 | |||||||||
| Adicet Bio, Inc. | ACET | → 0 | Neutral | 412.080 $ | -97.423 $ | -19,1 % | 1 | 509.503 $ | -274.919 $ | -35,0 % | 1 | 784.422 $ | +193.830 $ | +32,8 % | 1 |
| 47.884.476 $ | +14.085.048 $ | +11,7 % | 2 | 33.799.428 $ | -30.935.718 $ | -41,5 % | 2 | 700.444.832 $ | -784.557.877 $ | +42,9 % | 4 | ||||